Globally, over 170 million people (ca. 3% of the World’s population) are infected with the hepatitis C virus (HCV), which can cause serious liver diseases such as chronic hepatitis, evolving into subsequent health problems. Driven by the need to detect the presence of HCV, as an essential factor in diagnostic medicine, the monitoring of viral protein has been of great interest in developing simple and reliable HCV detection methods. Despite considerable advances in viral protein detection as an HCV disease marker, the current enzyme linked immunosorbent assay (ELISA) based detection methods using antibody treatment have several drawbacks. To overcome this bottleneck, an RNA aptamer become to be emerged as an antibody substitute in the application of biosensor for detection of viral protein. In this study, we demonstrated a streptavidin-biotin conjugation method, namely, the RNA aptamer sensor system that can quantify viral protein with detection level of 700 pg mL？1 using a biotinylated RNA oligonucleotide on an Octet optical biosensor. Also, we showed this method can be used to screen inhibitors of viral protein rapidly and simply on a biotinylated RNA oligonucleotide biosensor. Among the inhibitors screened, (？)-Epigallocatechin gallate showed high binding inhibition effect on HCV NS5B viral protein. The proposed method can be considered a real-time monitoring method for inhibitor screening of HCV viral protein and is expected to be applicable to other types of diseases.
References
[1]
Castello, G; Scala, S; Palmieri, G; Curley, SA; Izzo, F. HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin. Immunol 2010, 134, 237–250, doi:10.1016/j.clim.2009.10.007. 19910258
[2]
Maheshwari, A; Thuluvath, PJ. Management of acute hepatitis C. Clin. Liver Disease 2010, 14, 169–176, doi:10.1016/j.cld.2009.11.007.
[3]
Pawlotsky, JM. Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol 2006, 299, 261–284. 16568902
[4]
Reed, KE; Rice, CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol 2000, 242, 55–84. 10592656
[5]
De Francesco, R; Tomei, L; Altamura, S; Summa, V; Migliaccio, G. Approaching a new era for hepatitis C virus therapy: Inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 2003, 58, 11–16.
[6]
Bressanelli, S; Tomei, L; Roussel, A; Incitti, I; Vitale, RL; Mathieu, M; De Francesio, R; Rey, FA. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Nat. Acad. Sci. USA 1999, 96, 13034–13039, doi:10.1073/pnas.96.23.13034. 10557268
[7]
Yamashita, T; Kaneko, S; Shirota, Y; Qin, W; Nomura, T; Kobayashi, K; Murakami, S. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. J. Biol. Chem 1998, 273, 15479–15486, doi:10.1074/jbc.273.25.15479. 9624134
Gaudy, C; Thevenas, C; Tichet, J; Mariotte, N; Goudeau, A; dubois, F. Usefulness of the hepatitis C virus core antigen assay for screening of a population undergoing routine medical checkup. J. Clin. Microbiol 2005, 43, 1722–1726, doi:10.1128/JCM.43.4.1722-1726.2005. 15814991
[10]
Tang, Y; Li, H; Roberto, A; Warner, D; Yen-Lieberman, B. Detection of hepatitis C virus by a user-developed reverse transcriptase-PCR and use of amplification products for subsequent genotyping. J. Clin. Virol 2004, 2, 148–152.
[11]
Jayasena, SD. Aptamers: An emerging class of molecules that rival antibodies in diagnostics. Clin. Chem 1999, 45, 1628–1650. 10471678
[12]
Breaker, RR. DNA enzymes. Nat. Biotech 1997, 15, 427–431, doi:10.1038/nbt0597-427.
[13]
Riccardi, CS; Kranz, C; Kowalik, J; Yamanaka, H; Mizaikoff, B; Josowicz, M. Label-free DNA detection of hepatitis C virus based on modified conducting polypyrrole films at microelectrodes and AFM-tip integrated electrodes. Anal. Chem 2008, 80, 237–245, doi:10.1021/ac701613t. 18034460
[14]
Zheng, D; Seferos, DS; Giljohann, DA; Patel, PC; Mirkin, CA. Aptamer Nano-flares for Molecular Detection in Living Cells. Nano Lett 2009, 9, 3258–3261, doi:10.1021/nl901517b. 19645478
[15]
Tuerk, C; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249, 505–510, doi:10.1126/science.2200121. 2200121
[16]
Burgstaller, P; Girod, A; Blind, M. Aptamers as tools for target prioritization and lead identification. Drug Disco. Today 2002, 7, 1221–1228, doi:10.1016/S1359-6446(02)02522-9.
[17]
Gold, L; Allen, P; Binkley, J; Brown, D; Schneider, D; Eddy, SR. RNA: The shape of things to come, in The RNA World; Gestelend, RF, Atkins, JF, Eds.; Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 1993; pp. 497–510.
[18]
Abdiche, Y; Malashock, D; Pinkerton, A; Pons, J. Determining kinetics and affinities of protein interactions using a parallel real-time label-free Biosensor. Anal. Biochem 2008, 377, 209–217, doi:10.1016/j.ab.2008.03.035. 18405656
[19]
Laemmli, UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227, 680–685, doi:10.1038/227680a0. 5432063
[20]
Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem 1976, 72, 248–254, doi:10.1016/0003-2697(76)90527-3. 942051
[21]
Lotze, MT. Label-Free, Real-Time Detection System for Molecular Interaction Analysis. US Patent 20,090,147,264 2009.
Golemba, MD; Lello, FAD; Bessone, F; Fay, F; Benetti, S; Jones, LR; Campos, RH. High prevalence of hepatitis C virus genotype 1b infection in a small town of argentina, Phylogenetic and Bayesian Coalescent analysis. PloS One 2010, 5, e8751, doi:10.1371/journal.pone.0008751. 20090919
[24]
Roh, C; Lee, HY; Kim, SE; Jo, SK. A highly sensitive and selective viral protein detection method based on RNA oligonucleotide nanoparticle. Int. J. Nanomed 2010, 5, 323–329.
[25]
Ciesek, S; Steinmann, E; Wedemeyer, H; Manns, MP; Neyts, J; Tautz, N; Madan, V; Bartenschlager, R; Hahn, T; Pietschmann, T. Cyclosporine A inhibits hepatitis C virus nonstrucutural protein 2 through cyclophilin A. Hepatology 2009, 5, 1638–1645.
[26]
Ivanov, AV; Kozlov, MV; Kuzyakin, AO; Kostyuk, DA; Tunitskaya, VL; Kochetkov, SN. New non_nucleoside inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Biochemitry (Moscow) 2004, 69, 782–788, doi:10.1023/B:BIRY.0000040204.82885.f1.
[27]
Kozlov, MV; Polyakov, KM; Ivanov, AV; Filippova, SE; Kuzyakin, AO; Tunitskaya, VL; Kochetkov, SN. Hepatitis C virus RNA-dependent RNA polymerase: Study on the inhibition mechanism by pyrogallol derivatives. Biochemitry (Moscow) 2006, 71, 1021–1026, doi:10.1134/S0006297906090112.
